Paraflex

(chlorzoxazone)

ApprovedSmall molecule

WWim Janssens

Paraflex is one of 13 small molecule programs targeting Bruxism. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

BruxismActive, not recruiting

BruxismApproved

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Bruxism

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Approved

2 2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

2 3

XEOMIN

MMerz Pharmaceuticals GmbH

Paraflex

1 5

Xeomin

MMerz Therapeutics GmbH

Phase 3

1 6

Dysport

GGalderma R&D

Preclinical

1 7

Botox

AbbVie

Preclinical

2 8

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

2 9

Pharmacotherapy

UUniversity of Pittsburgh

Preclinical

1 10

Melissa

UUniversidade Federal do Rio de Janeiro

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Knee Arthroplasty1 trial

Chlorzoxazone in Hip and Knee Arthroplasty

Completed·NNorthern Orthopaedic Division, Denmark·Phase 4·NCT02405104·400 enrolled

Bruxism1 trial

Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain

Recruiting·UUniversity of Baghdad·Phase 4·NCT07109882·60 enrolled

ACL1 trial

Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05257447·19 enrolled

Metabolism1 trial

A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers

Completed·SSwedish Orphan Biovitrum·Phase 1·NCT03103568·36 enrolled

Moderate to Severe Postoperative Pain1 trial

The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery

Completed·RRigshospitalet, Denmark·Phase 4·NCT01933542·110 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

PARAFLEX

NDA NDA011300

Jun 15, 1987

PARAFON FORTE DSC

NDA NDA011529

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for chlorzoxazone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chlorzoxazone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chlorzoxazone. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011529). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wim Janssens company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWim Janssens

Paraflex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Knee Arthroplasty1 trial

Bruxism1 trial

ACL1 trial

Metabolism1 trial

Moderate to Severe Postoperative Pain1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News